参考文献/References:
[1]国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会“中国成人肥厚型心肌病诊断与治疗指南2023”专家组,宋雷,等. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志 ,2023,38(1):1-33.
[2]Ho JE,Shi L,Day SM,et al. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy[J]. Open Heart,2017,4(2):e000615.
[3] Essayagh B,Resseguier N,Michel N,et al. Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy[J]. Arch Cardiovasc Dis,2021,114(2):96-104.
[4]Wu G,Liu J,Wang S,et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy[J]. Heart,2021,107(19):1576-1583.
[5]Bégué C,M?rner S,Brito D,et al. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy[J]. Heart,2020,106(3):196-202.
[6]Giannitsis E,Katus HA.Troponins:established and novel indications in the management of cardiovascular disease[J]. Heart,2018,104(29):1714-1722.
[7]Kubo T,Ochi Y,Baba Y,et al. Elevation of high-sensitivity cardiac troponin T and left ventricular remodelling in hypertrophic cardiomyopathy[J]. ESC Heart Fail,2020,7(6):3593-3600.
[8]Gommans DHF,Cramer GE,Fouraux MA,et al. Usefulness of high-sensitivity cardiac troponin T to predict long-term outcome in patients with hypertrophic cardiomyopathy[J]. Am J Cardiol,2021,152:120-124.
[9]Zhang Y,Liu M,Zhang C,et al. Role of biomarkers of myocardial injury to predict adverse outcomes in hypertrophic cardiomyopathy[J]. Circ Cardiovasc Qual Outcomes,2024,17(2):e010243.
[10]Cavus E,Muellerleile K,Schellert S,et al. CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy[J]. Clin Res Cardiol,2021,110(11):1757-1769.
[11]Schlittler M,Pramstaller PP,Rossini A,et al. Myocardial fibrosis in hypertrophic cardiomyopathy:a perspective from fibroblasts[J]. Int J Mol Sci,2023,24(19):14845.
[12]Massoullié G,Sapin V,Ploux S,et al. Low fibrosis biomarker levels predict cardiac resynchronization therapy response[J]. Sci Rep,2019,9(1):6103.
[13]Rixon C,Andreassen K,Shen X,et al. Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy[J]. ESC Heart Fail,2023,10(2):858-871.
[14]Duprez DA,Gross MD,Kizer JR,et al. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction:MESA(Multi-Ethnic Study of Atherosclerosis)[J]. J Am Heart Assoc,2018,7(5):e007885.
[15]Duprez DA,Heckbert SR,Alonso A,et al. Collagen biomarkers and incidence of new onset of atrial fibrillation in subjects with no overt cardiovascular disease at baseline:the multi-ethnic study of atherosclerosis[J]. Circ Arrhythm Electrophysiol,2018,11(10):e006557.
[16]Foussier C,Barral PA,Jerosh-Herold M,et al. Quantification of diffuse myocardial fibrosis using CMR extracellular volume fraction and serum biomarkers of collagen turnover with histologic quantification as standard of reference[J]. Diagn Interv Imaging,2021,102(3):163-169.
[17]Serraino GF,Jiritano F,Costa D,et al. Metalloproteinases and hypertrophic cardiomyopathy:a systematic review[J]. Biomolecules,2023,13(4):665.
[18]Yang C,Qiao S,Song Y,et al. Procollagen type I carboxy-terminal propeptide(PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy[J]. Cardiovasc Pathol,2019,43:107150.
[19]Bi X,Yang C,Song Y,et al. Matrix metalloproteinases increase because of hypoperfusion in obstructive hypertrophic cardiomyopathy[J]. Ann Thorac Surg,2021,111(3):915-922.
[20]Nangia-Makker P,Hogan V,Balan V,et al. Chimeric galectin-3 and collagens:biomarkers and potential therapeutic targets in fibroproliferative diseases[J]. J Biol Chem,2022,298(12):102622.
[21]Gawor M,?piewak M,Janas J,et al. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy[J]. Kardiol Pol,2017,75(10):997-1004.
[22]Song B,Yao B,Dang H,et al. Soluble ST2,Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy:a correlation analysis[J]. Cardiovasc Diagn Ther,2020,10(2):145-152.
[23]Zhu L,Wang J,Wang Y,et al. Plasma uric acid as a prognostic marker in patients with hypertrophic cardiomyopathy[J]. Can J Cardiol,2015,31(10):1252-1258.
[24]Wang Z,Xu Y,Liao H,et al. U-shaped association between serum uric acid concentration and mortality in hypertrophic cardiomyopathy patients[J]. Ups J Med Sci,2020,125(1):44-51.
[25]Rizo-Téllez SA,Sekheri M,Filep JG.C-reactive protein:a target for therapy to reduce inflammation[J]. Front Immunol,2023,14:1237729.
[26]Burger PM,Koudstaal S,Mosterd A,et al. C-reactive protein and risk of incident?heart?failure in patients with?cardiovascular disease[J]. J Am Coll Cardiol,2023,82(5):414-426.
[27]Zhu L,Zou Y,Wang Y,et al. Prognostic significance of plasma high-sensitivity C-reactive protein in patients with hypertrophic cardiomyopathy[J]. J Am Heart Assoc,2017,6(2):e004529.
[28]Harding D,Fanti S,Marelli-Berg F. Tumour necrosis factor-α in cardiac inflammation:friend or foe?[J]. Cardiovasc Res ,2024,120(1):1-2.
[29]Fang L,Ellims AH,Beale AL,et al. Systemic inflammation is associated with myocardial fibrosis,diastolic dysfunction,and cardiac hypertrophy in patients with hypertrophic cardiomyopathy[J]. Am J Transl Res,2017,9(11):5063-5073.
[30]Dhaun N,Webb DJ. Endothelins in cardiovascular biology and therapeutics[J]. Nat Rev Cardiol,2019,16(8):491-502.
[31]Wang Y,Tang Y,Zou Y,et al. Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy[J]. Int J Cardiol,2017,243:283-289.
[32]Liu L,Wu L,Zheng L,et al. Associations between multiple circulating biomarkers and the presence of atrial fibrillation in hypertrophic cardiomyopathy with or without left ventricular outflow tract obstruction[J]. Int Heart J,2019,60(2):327-335.
[33]Cordts K,Seelig D,Lund N,et al. Association of asymmetric dimethylarginine and diastolic dysfunction in patients with hypertrophic cardiomyopathy[J]. Biomolecules,2019,9(7):277.
[34]Fernlund E,Gyllenhammar T,Jablonowski R,et al. Serum biomarkers of myocardial remodeling and coronary dysfunction in early stages of hypertrophic cardiomyopathy in the young[J]. Pediatr Cardiol,2017,38(4):853-863.
[35]Ntelios D,Georgiou E,Alexouda S,et al. A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases:the case of hypertrophic cardiomyopathy[J]. Heart Fail Rev,2022,27(1):281-294.
[36]Helms AS,Thompson AD,Glazier AA,et al. Spatial and functional distribution of MYBPC3 pathogenic variants and clinical outcomes in patients with hypertrophic cardiomyopathy[J]. Circ Genom Precis Med,2020,13(5):396-405.
[37]Wang Z,Liao H,Chen X,et al. Hyperuricemia:risk factor for thromboembolism in hypertrophic cardiomyopathy patients[J]. Intern Emerg Med,2020,15(7):1231-1237.
[38]Shimada YJ,Raita Y,Liang LW,et al. Comprehensive proteomics profiling reveals circulating biomarkers of hypertrophic cardiomyopathy[J]. Circ Heart Fail,2021,14(7):e007849.
[39]Shimada YJ,Raita Y,Liang LW,et al. Prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy using proteomics profiling[J]. Circ Genom Precis Med,2022,15(6):e003546.
[40] Liang LW,Raita Y,Hasegawa K,et al. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy[J]. Heart,2022,108(22):1807-1814.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]晏露 李欣 柳志红.不同生物标志物在急性肺血栓栓塞症中的应用价值[J].心血管病学进展,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
YAN Lu,LI Xin,LIU Zhihong.The unction of Different Biomarkers in Acute Pulmonary Embolism[J].Advances in Cardiovascular Diseases,2019,(1):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
[5]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[6]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(1):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[7]冯小梅 李彦红.Ⅰ型前胶原羧基端肽和Ⅲ型前胶原氨基端肽在心肌纤维化的研究进展[J].心血管病学进展,2020,(5):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
FENG Xiaomei,LI Yanhong.PCP and PNP in Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2020,(1):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
[8]李谧 李琳.生长分化因子-15在心房颤动中的研究及应用进展[J].心血管病学进展,2020,(7):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
LI Mi,LI Lin.Research and Application of Growth Differentiation Factor-15 in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(1):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
[9]于博文 修成奎 王雪 杨静 雷燕.内皮微粒在临床中的研究进展及应用[J].心血管病学进展,2021,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Bowen,XIU Chengkui,WANG Xue,et al.Research Progress and Application of Endothelial Microparticles in Clinic[J].Advances in Cardiovascular Diseases,2021,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[10]刘月娥 关秀茹.循环miRNA作为冠心病潜在生物标志物的研究进展[J].心血管病学进展,2021,(2):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]
LIU Yuee,GUAN Xiuru.Research Progress of Circulating Mirna as a Potential Biomarker of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2021,(1):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]